spacer
home > ebr > summer 2004 > functional genomics in trypanosomes: using rna interference to assign gene function and validate drug targets in tropical disease agents
PUBLICATIONS
European Biopharmaceutical Review

Functional Genomics in Trypanosomes: Using RNA Interference to Assign Gene Function and Validate Drug Targets in Tropical Disease Agents

The World Health Organization has designated many tropical protozoan pathogens as high priority re-emergent disease agents. Asymmetric funding - many of these pathogens affect citizens of countries with low or no economic wealth - has meant that the development of new therapeutics is slow or non-existent. For researchers interested in Trypanosoma brucei, the causative agent of human African sleeping sickness, a combination of renewed interest, completion of the genome project and RNA interference technology may herald a new period of advance in both therapeutic development and understanding of basic biology. Can the research community deliver?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Mark C Field, Department of Biological Sciences at Imperial College, London, and Dr Mark Carrington, Department of Biochemistry at the University of Cambridge, UK

Dr Mark C Field is at the Department of Biological Sciences, Imperial College. He was educated at Oxford Univeristy and completed his doctoral work there at the Glycobiology Institute on glyoprotein structure and function. His postdoctoral career began in the US where he started to work on trypanosomatids at the Rockefeller and Stanford Universities, as well as a short period at Genentech Inc. In 1994, he established his own research group at Imperial College, London, which focuses on the molecular cell biology of Trypanosoma brucei.


Dr Mark Carrington is at the Department of Biochemistry, University of Cambridge. He was educated at Cambridge, obtaining his PhD in Plant Molecular Biology. He has worked on trypanosomes since the start of his postdoctoral career and has extensive experience in the study of protein structure and RNA processing, and is interested in the development of therapeutics based on surface proteins and on host-resistance mechanisms.

spacer
Dr Mark C Field
spacer
spacer
spacer
Dr Mark Carrington
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Changing Structural Landscape for Comparator Drug Supply

ADAllen Pharma

TransCelerate Biopharma is focused on advancing innovation in R&D, identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients. In 2013, they announced its Clinical Trial Comparator Network initiative to show a mutual commitment to offer secure and rapid supply of comparator drug products. The aim of this article is to unpack the section on 'Comparator Drugs' and analyse the rationale for attempting to achieve their objectives.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement